CN1491661A - Total penoniforn preparation and its use - Google Patents
Total penoniforn preparation and its use Download PDFInfo
- Publication number
- CN1491661A CN1491661A CNA031534961A CN03153496A CN1491661A CN 1491661 A CN1491661 A CN 1491661A CN A031534961 A CNA031534961 A CN A031534961A CN 03153496 A CN03153496 A CN 03153496A CN 1491661 A CN1491661 A CN 1491661A
- Authority
- CN
- China
- Prior art keywords
- radix paeoniae
- injection
- general glycoside
- water
- glycoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 9
- 230000002537 thrombolytic effect Effects 0.000 claims abstract description 7
- 239000007787 solid Substances 0.000 claims abstract description 4
- 229930182470 glycoside Natural products 0.000 claims description 61
- 150000002338 glycosides Chemical class 0.000 claims description 59
- 239000007924 injection Substances 0.000 claims description 30
- 238000002347 injection Methods 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 20
- 239000008215 water for injection Substances 0.000 claims description 17
- 238000012856 packing Methods 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 238000003556 assay Methods 0.000 claims description 11
- 239000003708 ampul Substances 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 7
- 238000007789 sealing Methods 0.000 claims description 7
- 238000000108 ultra-filtration Methods 0.000 claims description 7
- 230000002785 anti-thrombosis Effects 0.000 claims description 6
- 235000005687 corn oil Nutrition 0.000 claims description 6
- 239000003978 infusion fluid Substances 0.000 claims description 6
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 claims description 5
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 2
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 abstract description 14
- 238000002474 experimental method Methods 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 4
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 206010053567 Coagulopathies Diseases 0.000 description 5
- 235000006484 Paeonia officinalis Nutrition 0.000 description 5
- 239000009277 Panax notoginseng extract Substances 0.000 description 5
- 230000035602 clotting Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241001106477 Paeoniaceae Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- LATYEZNGPQKAIK-UHFFFAOYSA-N 6'-O-benzoylpaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-UHFFFAOYSA-N 0.000 description 2
- 241000736199 Paeonia Species 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- VIWQCBZFJFSCLC-UHFFFAOYSA-N alpha-benzoyloxypaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- -1 lactone glycoside Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- LATYEZNGPQKAIK-HRCYFWENSA-N Benzoylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-HRCYFWENSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical group C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 239000009835 oxypaeoniflora Substances 0.000 description 1
- FCHVXNVDFYXLIL-QYDSDWLYSA-N oxypaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@@]1(C[C@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=C(O)C=C1 FCHVXNVDFYXLIL-QYDSDWLYSA-N 0.000 description 1
- RLXWQODPAWIVOI-UHFFFAOYSA-N oxypaeoniflorin Natural products OCC1OC(OC23CC4C5(O)CC2OC(O5)C34COC(=O)c6ccc(O)cc6)C(O)C(O)C1O RLXWQODPAWIVOI-UHFFFAOYSA-N 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Abstract
The present invention discloses a kind of total penoniforin preparation with thrombolysis activity and used as medicine for treating cardiac and cerebral vascular diseases. The preparation contains total penoniforin in 50-99 % of solid matter weight. Pharmacodynamical experiment shows that the preparation has obvious thrombolytic and thrombosis resisting effect.
Description
Affiliated field
The present invention relates to a kind of cardiovascular medicament Radix Paeoniae general glycoside preparation and preparation method thereof, belong to medical pharmaceutical field, particularly belong to Chinese medicine antithrombotic reagent pharmaceutical technology field with thrombolytic and antithrombotic acitivity.
Background technology
Radix Paeoniae (Paeonia Lactflora Pall) is divided into two kinds of the Radix Paeoniae Alba and Radix Paeoniae Rubra, starts from Song's Holy Benevolent Prescriptions.Its main effective ingredient is paeoniflorin (Paeoniforin), peony lactone glycoside (Albiforin), and hydroxypaeoniflorin (Oxypaeoniflorin), benzoylpaeoniflorin monoterpene glycoside compounds such as (Benzoyl paeoniflorin) is called for short the Radix Paeoniae general glycoside.The modern plants chemistry thinks that Radix Paeoniae Alba total glycosides is the active component in the Radix Paeoniae, mainly is present in the root bark portion of Radix Paeoniae.Traditional medicine thinks, Radix Paeoniae Rubra can clearing away heat and cooling blood, and eliminating stasis to stop pain clinically, is diseases such as monarch drug prescription therapeutic ischemic angiocardiopathy and cerebrovascular with Radix Paeoniae Rubra or with Radix Paeoniae Rubra.
Retrieve in the relevant patent and data of literatures of having applied for Radix Paeoniae, do not mention that also with content be the pharmaceutical preparation that the Radix Paeoniae general glycoside of 50-99% is made, effect experiment proves, injection, injectable powder, infusion solution and the lipomul made of the Radix Paeoniae general glycoside of content has significant thrombolytic and antithrombotic effect thus.
Summary of the invention
The invention discloses a kind of cardiovascular medicament Radix Paeoniae general glycoside preparation with thrombolytic and antithrombotic acitivity and preparation method thereof, the Radix Paeoniae general glycoside accounts for the 50-99% of total solid in the preparation of making.Its dosage form is injection, injectable powder, infusion solution and lipomul.
The solid constituent of Radix Paeoniae total glycoside injection is made up of Radix Paeoniae general glycoside and pharmaceutic adjuvant, and wherein the total salidroside content of Radix Paeoniae is 50%-99%.
The Radix Paeoniae total glycoside injection mainly contains injection, injectable powder, infusion solution and lipomul.Its preparation method is different according to different dosage forms.
The Radix Paeoniae general glycoside is dissolved with water for injection, after the injection of adding metering dissolved with the water solublity pharmaceutic adjuvant, regulator solution PH to 6.0-7.0 was after the microporous filter membrane ultrafiltration, add the injection water and add to ormal weight, carry out packing or carry out dried according to the dosage form needs again.
Preparation Radix Paeoniae general glycoside injection, the content of the interior Radix Paeoniae general glycoside of injection is 10-100mg/ml before the packing, be sub-packed in the ampoule bottle, every 2ml, the sealing by fusing sterilization, after the assay was approved, packing is promptly.
Preparation Radix Paeoniae general glycoside infusion solution, the content of Radix Paeoniae general glycoside is 1-10mg/ml in the preceding injection of packing, is packed as 100ml, 150ml, 200ml in corresponding infusion bottle, rolls lid, after the assay was approved, packing is promptly.
Preparation Radix Paeoniae general glycoside injectable powder, after the Radix Paeoniae general glycoside doubly measured water for injection dissolving with 5-10, after the injection of adding metering fully dissolves with the water solublity pharmaceutic adjuvant, transfer PH to 6.0-7.0, filter, in 40 ℃ of following vacuum dryings, aseptic subpackaged in the 5ml cillin bottle, every bottle contains Radix Paeoniae general glycoside 100-250mg, rolls lid, after the assay was approved, packing promptly.
Preparation Radix Paeoniae general glycoside lyophilized injectable powder, with the Radix Paeoniae general glycoside after refining, doubly measure the water for injection dissolving with 5-10 after, the injection water solublity pharmaceutic adjuvant that adds metering, transfer PH to 5.0-7.0, filter, be diluted to every milliliter with water for injection and contain Radix Paeoniae general glycoside 10-20mg, be sub-packed in the ampoule, every 10ml, after lyophilization, sealing by fusing, after the assay was approved, packing promptly.
Below by embodiment cardiovascular medicament total paeony glycoside preparation with thrombolytic and antithrombotic acitivity of the present invention and preparation method thereof is described further.
Embodiment 1:
Preparation Radix Paeoniae general glycoside aqueous injection.
1kg is dissolved in the 100L water for injection with the Radix Paeoniae general glycoside, is made into 10mg/ml, regulates PH to 6.0.After the microporous filter membrane ultrafiltration, replenish water for injection to ormal weight, fill is in ampoule bottle, and the sealing by fusing sterilization through after the assay was approved, is packed promptly.
Embodiment 2
Preparation Radix Paeoniae general glycoside injectable powder.
Radix Paeoniae general glycoside 1kg is dissolved in an amount of 100L water for injection, the pharmaceutic adjuvant that adds metering, regulate PH to 6.0, after the microporous filter membrane ultrafiltration, vacuum drying gets Radix Paeoniae general glycoside aseptic powder, and aseptic powder is sub-packed in the cillin bottle, make every bottle and contain Radix Paeoniae general glycoside aseptic powder 100mg, three specifications of 150mg, 200mg, roll lid, through after the assay was approved, packing promptly.
Embodiment 3
Preparation Radix Paeoniae general glycoside lyophilized injectable powder
With Radix Paeoniae general glycoside 1kg, after the dissolving of 5 times of amount water for injection, add the injection water solublity pharmaceutic adjuvant of metering, regulate PH to 6.0, filter, be loaded in the ampoule bottle, every 10ml, after lyophilization, sealing by fusing, after the assay was approved, packing is promptly.
Embodiment 4
Preparation Radix Paeoniae general glycoside lipomul.
With Radix Paeoniae general glycoside 1kg, be dissolved in the 100L injection fat solvent (forming) by water for injection and emulsifying agent, be made into the solution of 10mg/ml, regulate PH to 6.0.After the microporous filter membrane ultrafiltration, be sub-packed in 2ml, the 5ml ampoule, after the assay was approved, packing is promptly.
The pharmacological effect experiment
Experiment 1, Radix Paeoniae general glycoside are to the thrombotic influence of rats in vitro
Experiment material
1. medicine: Radix Paeoniae general glycoside powder pin: 50mg/ props up; The injection XUESHUANTONG: 50mg/ props up.
2. animal: 40 of healthy male Wistar rats, body weight 210.72 ± 9.0g.
Experimental technique
40 rats are divided into 4 groups (10 every group) at random: 1. matched group (0.9% sodium chloride injection, 5.0ml/kg), 2. Radix Paeoniae general glycoside powder pin 20mg/kg dosage group, 3. Radix Paeoniae general glycoside powder pin 10mg/kg dosage group, 4. injection XUESHUANTONG 20mg/kg dosage group.Each treated animal by described dosage with the injection volume of 5.0ml/kg through the tail vein injection administration, once a day, successive administration 3 days, 30min after the last administration with pentobarbital sodium (30.0mg/kg) anesthesia, is used for external thrombus from abdominal aortic blood 2ml and forms and measure.
External thrombus forms to be measured: according to the Chandler in vitro method, at once blood is injected in the rotating ring, the blood volume of injection is full of rotating ring below 1/2, rapidly sealing, put on the thrombosis instrument, rotation 10min, inclining thrombosis, the normal saline washing, measure length, the weighing weight in wet base is put 80 ℃ of baking oven 3h with the thrombosis bar, claims its dry weight after the constant weight.
Experimental result:
Table 1. Radix Paeoniae general glycoside is to the thrombotic influence of rats in vitro (X ± SD)
| Group | Dosage (/kg) | Number of animals | Thrombosis | ||
| Length (mm) | Weight in wet base (mg) | Dry weight (mg) | |||
| Matched group | ????10 | ??23.1±1.2 | ??154.4±12.0 | ??27.2±1.5 | |
| The injection XUESHUANTONG | ??20mg | ????10 | ??16.7±2.0 | ??132.6±20.3 | ??19.4±4.3 |
| Radix Paeoniae general glycoside powder pin | ??10mg | ????10 | ??20.9±1.3 | ??130.7±13.8 | ??24.7±5.2 |
| Radix Paeoniae general glycoside powder pin | ??20mg | ????10 | ??16.9±2.7 | ??131.0±21.8 | ??20.3±4.0 |
Annotate: compare P＜0.01 with matched group
By table 1 as seen, compare with matched group, the thrombosis length of Radix Paeoniae general glycoside powder pin 20mg/kg and 10mg/kg dosage group all obviously shortens (P＜0.01), and wet weight of thrombus and dry weight all obviously alleviate (P＜0.01), and the thrombosis dry weight has the trend of alleviating; The thrombosis dry weight of injection XUESHUANTONG group obviously alleviates (P＜0.05), and thrombosis length has shortening trend, and wet weight of thrombus has the trend of alleviating.Show that Radix Paeoniae general glycoside powder needle set has the effect that suppresses thrombosis, blood viscosity lowering, to compare drug effect suitable with XUESHUANTONG.
Experiment 2: the Radix Paeoniae general glycoside is to the influence of clotting time of mice
50 of kunming mices are divided into 5 groups at random, each treated animal by described dosage with the injection volume of 5.0ml/kg through the tail vein injection administration, once a day, successive administration 3 days, behind the 1h, abdominal aortic blood is used the determination of tube method clotting time after the last administration.The result: three kinds of dosage all obviously prolong the clotting time of mice.
Experimental result:
Table 2 Radix Paeoniae general glycoside is to the influence of clotting time of mice (n=10, x ± s)
Group dosage (mg/kg) clotting time (s)
Capacity such as normal saline 55.1 ± 10.8
Total paeony glycoside (greatly) 20 70.8 ± 12.0
Total paeony glycoside (in) 10 64.5 ± 12.2
Total paeony glycoside (little) 5 57.6 ± 9.7
Aspirin 10 67.0 ± 10.6
Compare P＜0.01 with the normal saline group
Claims (7)
1. cardiovascular medicament Radix Paeoniae general glycoside preparation with thrombolytic and antithrombotic acitivity is characterized in that the total salidroside content of Radix Paeoniae in the preparation accounts for the 50%-99% of total solid.Its dosage form is injection, injectable powder, infusion solution and lipomul.
2,, form as active component and pharmaceutic adjuvant by the Radix Paeoniae general glycoside according to the injection in the claim 1.
3, according to the aqueous injection in the claim 1, form by Radix Paeoniae general glycoside and water for injection and water soluble adjuvant, it is characterized in that: the Radix Paeoniae general glycoside is dissolved in an amount of water for injection, adds the injection water soluble adjuvant of metering, regulate PH to 5.0-7.0, after the microporous filter membrane ultrafiltration, replenish water for injection to ormal weight, fill is in ampoule bottle or in the infusion bottle, sealing by fusing/roll lid, through after the assay was approved, packing promptly.The total salidroside content of Radix Paeoniae is 3.0-30.0mg/ml in the injection, and specification is 2ml, 5ml.Infusion solution contains Radix Paeoniae general glycoside 2.0-30.0mg/ml, and specification is 50ml, 100ml, 150ml and 200ml.
4, according to the injectable powder in the claim 1, form by Radix Paeoniae general glycoside and water for injection dissolubility pharmaceutic adjuvant, it is characterized in that: the Radix Paeoniae general glycoside is dissolved in an amount of water for injection, adds the pharmaceutic adjuvant of metering, adjusting PH is 5.0-7.0, after the microporous filter membrane ultrafiltration, low-temperature vacuum drying, aseptic subpackaged in cillin bottle, every bottle contains Radix Paeoniae general glycoside 10-200mg, roll lid, through after the assay was approved, packing promptly.
5, according to the lyophilized injectable powder in the claim 1, form by Radix Paeoniae general glycoside and water for injection dissolubility pharmaceutic adjuvant, it is characterized in that: the Radix Paeoniae general glycoside is dissolved in an amount of water for injection, adds the pharmaceutic adjuvant of metering, adjusting PH is 5.0-7.0, after the microporous filter membrane ultrafiltration, be sub-packed in the ampoule bottle, the total salidroside content of Radix Paeoniae is 10-200mg in the per ampoule bottle, sealing by fusing after lyophilization, after the assay was approved, packing promptly.
6, according to the lipomul in the claim 1, be the Radix Paeoniae general glycoside to be dissolved in the injection fat solvent (comprise water for injection, emulsifying agent and pharmaceutic adjuvant), be sub-packed in behind the mix homogeneously in the ampoule bottle, the total salidroside content of Radix Paeoniae is 3.0-30.0mg/ml in the per ampoule bottle, and specification is 2ml, 5ml.
7, extract from the plant amedica Radix Paeoniae Rubra or the Radix Paeoniae Alba according to the Radix Paeoniae general glycoside in the claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031534961A CN1491661A (en) | 2003-08-15 | 2003-08-15 | Total penoniforn preparation and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031534961A CN1491661A (en) | 2003-08-15 | 2003-08-15 | Total penoniforn preparation and its use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1491661A true CN1491661A (en) | 2004-04-28 |
Family
ID=34240756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031534961A Pending CN1491661A (en) | 2003-08-15 | 2003-08-15 | Total penoniforn preparation and its use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1491661A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100592902C (en) * | 2004-05-10 | 2010-03-03 | 株式会社Lg生活健康 | The use of paeoniflorin in the preparation of skin aging care or skin aging prevention composition |
| EP1767210A4 (en) * | 2004-07-02 | 2010-09-08 | Shanghai Inst Materia Medica | MEDICAL USE OF PAEONIFLORIN |
| CN1706397B (en) * | 2005-02-04 | 2011-11-16 | 沈阳药科大学 | Composition of paeoniflorin and peony lactone glycoside with function of increasing leukocyte |
-
2003
- 2003-08-15 CN CNA031534961A patent/CN1491661A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100592902C (en) * | 2004-05-10 | 2010-03-03 | 株式会社Lg生活健康 | The use of paeoniflorin in the preparation of skin aging care or skin aging prevention composition |
| EP1767210A4 (en) * | 2004-07-02 | 2010-09-08 | Shanghai Inst Materia Medica | MEDICAL USE OF PAEONIFLORIN |
| CN1706397B (en) * | 2005-02-04 | 2011-11-16 | 沈阳药科大学 | Composition of paeoniflorin and peony lactone glycoside with function of increasing leukocyte |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012512147A5 (en) | ||
| CN1491661A (en) | Total penoniforn preparation and its use | |
| CN1255121C (en) | A kind of preparation method of rhodiola rosea medicinal preparation | |
| CN1259054C (en) | Application of gentiopicrin in preparing medication for restraining hepatitis B virus | |
| CN1565465A (en) | Injection preparation containing breviscapine active component and its preparation method | |
| CN1359682A (en) | Breviscapine-phosphotide compound and its preparing process | |
| CN103446041B (en) | Leuprorelin slow-controlled drug release stick and preparation method thereof | |
| CN1426783A (en) | Application of evodiamine in the preparation of medicine | |
| CN1268361C (en) | Chinese traditional medicine composition for treating cardiovascular and cerebrovascular diseases | |
| CN1248688C (en) | Targeting hydroxycamptothecin bean phospholipid nano freeze-dried powder injection preparation and preparation method thereof | |
| CN1415301A (en) | Compound recipe formula containing kurarinone prostaglandin E1 and aspirin, its preparation method and application | |
| CN1836670A (en) | Microsphere injection for treating ophthalmopathy | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN101474315A (en) | Effective component group of stem-bark or root-bark of Daphne giraldii as well as preparation method and use thereof | |
| CN100551404C (en) | Preparation, detection method and use of diuretic and swelling medicinal composition | |
| CN1765361A (en) | Novel bulleyaconitine A powder injection and its production method | |
| CN106860857A (en) | A kind of chinese-western medicine preparation for treating the yellowish-white dysentery of pig | |
| CN1879714A (en) | A Chinese medicinal composition for treating thrombus | |
| CN108785249A (en) | The dosage form of the nanometer superfine powder containing triphenyl diamidine | |
| CN1899352A (en) | Chinese medicine effective part composition for supplementing qi and recovering pulse | |
| CN1813836A (en) | Medicinal composition for treating cardio-cerebrovascular disease | |
| CN1167425C (en) | Application of aminoaglycon antibiotics in preparing compound oral liquid for treating gastroenteritis | |
| CN1733013A (en) | Novel route for administering hairy holly injection and preparation process thereof | |
| CN1899329A (en) | Medicinal composition with blood fat reducing function | |
| CN1258373C (en) | Medicine for treating lumbosacral pain and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Cao Jing Document name: Deemed as a notice of withdrawal |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |